Evaluative Sciences Research, MS Center at Dartmouth, DHMC, Lebanon, NH, USA.
J Neurol Sci. 2011 Mar 15;302(1-2):96-105. doi: 10.1016/j.jns.2010.11.003. Epub 2010 Dec 16.
Early and more recent systematic reviews of placebo controlled trials disagree about the relative efficacy of the commercially available INF-ß treatments in studies of adults with RRMS. A limitation of these reviews is that they have derived their findings almost entirely from the pivotal trials and placebo controlled studies.
To provide the first meta-analytic study of head-to-head and comparative trials of INF-ß agents in RRMS treatment.
OVID Medline and Cochrane Library electronic databases were searched using keywords "multiple sclerosis", "interferon beta-1a", and "interferon beta-1b". Using a standardized abstraction form, three reviewers independently abstracted MRI, relapse rate, and disability (EDSS) data. RevMan5 software was used to calculate relative risk (RR) and absolute risk differences (RD) based on event rates.
High dose treatment demonstrated superior relapse reduction and MRI stability compared to low dose treatment. There was also a trend observed in the aggregate analyses of disability progression (EDSS) favoring high dose treatment.
High dose INF-ß treatment demonstrated superior relapse control and MRI stability compared to low dose treatment in a systematic review of comparative studies. These results contradict those of earlier systematic reviews and support the conclusions of more recent systematic reviews of the placebo controlled trials.
早期和近期的安慰剂对照试验系统评价对 RRMS 成人研究中商业上可获得的 INF-ß 治疗的相对疗效存在分歧。这些综述的一个局限性是，它们几乎完全从关键试验和安慰剂对照研究中得出结论。
提供 INF-ß 药物在 RRMS 治疗中头对头和比较试验的首次荟萃分析研究。
使用关键字“多发性硬化症”、“干扰素 beta-1a”和“干扰素 beta-1b”在 OVID Medline 和 Cochrane Library 电子数据库中进行搜索。使用标准化的摘要表格，三位审查员独立提取 MRI、复发率和残疾（EDSS）数据。RevMan5 软件用于根据事件率计算相对风险 (RR) 和绝对风险差异 (RD)。
高剂量治疗与低剂量治疗相比，显示出更好的复发减少和 MRI 稳定性。在残疾进展（EDSS）的综合分析中也观察到高剂量治疗有利的趋势。
在比较研究的系统评价中，高剂量 INF-ß 治疗与低剂量治疗相比，显示出更好的复发控制和 MRI 稳定性。这些结果与早期系统评价的结果相矛盾，支持对安慰剂对照试验的更近期系统评价的结论。
